Ascendis Pharma

Ascendis Pharma A/S, established on September 21, 2006, is a clinical-stage biopharmaceutical company that utilizes its TransCon technology to develop a pipeline of optimized long-acting drug therapies to address significant unmet medical needs in large markets. Athira Pharma's investigational therapy, fosgonimeton, is a small molecule drug that enhances the activity of the HGF/MET signaling pathway. This pathway mediates natural repair mechanisms in a healthy nervous system. By targeting the repair mechanisms of neural pathways, fosgonimeton has the potential to alter disease progression.